Andrei Stoica
Chief Tech/Sci/R&D Officer bei BUTTERFLY NETWORK, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Andrei Stoica is currently the Chief Technology Officer at Butterfly Network, Inc. He previously worked as the Chief Technology Officer at BioTelemetry, Inc. and as the Vice President-Systems Development at IQVIA Holdings, Inc. He holds a doctorate degree from the University of South Carolina.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.04.2024 | 1 497 558 ( 0,82% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Andrei Stoica
| Unternehmen | Position | Beginn |
|---|---|---|
| BUTTERFLY NETWORK, INC. | Chief Tech/Sci/R&D Officer | 19.07.2021 |
Ehemalige bekannte Positionen von Andrei Stoica
| Unternehmen | Position | Ende |
|---|---|---|
| BIOTELEMETRY, INC. | Chief Tech/Sci/R&D Officer | - |
| IQVIA HOLDINGS INC. | Corporate Officer/Principal | - |
Ausbildung von Andrei Stoica
| University of South Carolina | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IQVIA HOLDINGS INC. | Health Services |
| BUTTERFLY NETWORK, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
BioTelemetry, Inc.
 BioTelemetry, Inc. Medical SpecialtiesHealth Technology BioTelemetry, Inc. provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized core laboratory services for clinical research. The firm also develops proprietary integrated patient management platform that incorporates wireless data transmission network. It operates through the following segments: Healthcare, and Research. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. The company was founded on April 22, 2013 and is headquartered in Malvern, PA. | Health Technology |
